These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19377079)

  • 1. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.
    Semeraro F; Ammollo CT; Semeraro N; Colucci M
    Haematologica; 2009 Jun; 94(6):819-26. PubMed ID: 19377079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
    J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.
    Carrieri C; Galasso R; Semeraro F; Ammollo CT; Semeraro N; Colucci M
    J Thromb Haemost; 2011 Jan; 9(1):154-62. PubMed ID: 20961395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO
    J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
    Nielsen VG; Kirklin JK
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):793-800. PubMed ID: 19002046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
    Bajzar L; Nesheim ME; Tracy PB
    Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
    J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
    Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
    J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor XII-dependent increases in thrombin activity induce carboxypeptidase-mediated attenuation of pharmacological fibrinolysis.
    Latacha MP; Schaiff WT; Eisenberg PR; Abendschein DR
    J Thromb Haemost; 2004 Jan; 2(1):128-34. PubMed ID: 14717976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
    Colucci M; Simioni P; Piro D; Prandoni P; Pagnan A; Semeraro N
    Haematologica; 2003 Dec; 88(12):1383-9. PubMed ID: 14687992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y; Honda Y
    J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
    J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
    Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
    J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism.
    Colucci M; Binetti BM; Tripodi A; Chantarangkul V; Semeraro N
    Blood; 2004 Mar; 103(6):2157-61. PubMed ID: 14630828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
    Schneider M; Nesheim M
    J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
    Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
    Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.